Get the Stockscreener App
3.81
0.52%
-0.02
Pre-market:
3.83
0.02
+0.52%
Jaguar Health Inc stock is traded at $3.81, with a volume of 72,789.
It is down -0.52% in the last 24 hours and down -55.23% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$3.83
Open:
$3.85
24h Volume:
72,789
Relative Volume:
0.56
Market Cap:
$5.06M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.2354
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
-4.75%
1M Performance:
-55.23%
6M Performance:
-88.09%
1Y Performance:
-95.79%
1-Day Range:
$3.76
$3.9199
1-Week Range:
$3.71
$4.13
52-Week Range:
$3.71
$110.75
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
3.81 | 5.06M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.44 | 114.49B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.60 | 52.36B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.58 | 39.81B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.96 | 35.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
262.41 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - The Oklahoman
Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Cani - GuruFocus
Jaguar Health Establishes First Site for Canalevia-CA1 Field Study - marketscreener.com
First Study Site Established for Jaguar Health Study of its FDA - GuruFocus
Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Canine Treatment | JAGX Stock News - GuruFocus
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | JAGX Stock News - GuruFocus
First FDA-Approved Dog Diarrhea Treatment Targets 6M Annual Cases with New Clinical Study - Stock Titan
Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2025 Earnings Call Transcript - MSN
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series - The Oklahoman
Jaguar Health Reports First Quarter 2025 Financials - The Columbus Dispatch
Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer By Investing.com - Investing.com South Africa
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer - Akron Beacon Journal
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series | JAGX Stock News - GuruFocus
Jaguar Health to Reveal Critical FDA Feedback on Breakthrough Phase 3 Breast Cancer Trial Results - Stock Titan
Jaguar Health (JAGX) Advances Plans for Crofelemer Application | - GuruFocus
Jaguar Health (JAGX) Advances Plans for Crofelemer Application | JAGX Stock News - GuruFocus
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days - The Columbus Dispatch
Jaguar Health Provides Update on Meeting with FDA Discussing Sta - GuruFocus
Breakthrough: FDA Meeting Could Fast-Track New Breast Cancer Treatment Following Positive Trial Data - Stock Titan
Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates - ACCESS Newswire
Small-cap biotech Jaguar Health’s stock jumps as it launches treatment for a painful side effect of cancer treatment - MSN
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series - The Oklahoman
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company - GuruFocus
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series | JAGX Stock News - GuruFocus
Jaguar Health CEO to Reveal New Orphan Drug Development Strategy: Key Updates Coming June 10 - Stock Titan
Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th - ACCESS Newswire
Knight Therapeutics and Jaguar Health Announce Strategic Partnership - ACCESS Newswire
Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance - ACCESS Newswire
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - The Columbus Dispatch
Jaguar Health (NASDAQ:JAGX) Upgraded at Wall Street Zen - Defense World
Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer - ACCESS Newswire
Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’ - MSN
Jaguar Health Announces $1.5M Direct Stock Offering - TipRanks
Jaguar Health prices 0.25M shares at $6.09 in registered direct offering - MSN
Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’ By Stocktwits - Investing.com India
Jaguar Health announces $1.5 million direct offering By Investing.com - Investing.com South Africa
Jaguar Health (JAGX) Announces Direct Offering and Private Placement | JAGX Stock News - GuruFocus
Jaguar Health announces $1.5 million direct offering - Investing.com India
Jaguar Health Prices Offering of Shares, Warrants - marketscreener.com
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | JAGX Stock News - GuruFocus
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.92%
7.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):